Drug Trial Radar · NCT05425745
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Jul 25, 2022
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be a placebo-controlled, double-blind, randomized, phase 3 study to Evaluate the Efficacy, Safety, and Tolerability of Obicetrapib in Participants with a History of Heterozygous Familial Hypercholesterolemia (HeFH).
Conditions
- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia
- Familial Hypercholesterolemia
- Lipid Metabolism Disorder
- Metabolic Disease
- Lipid Metabolism, Inborn Errors
- Genetic Disease, Inborn
- Hyperlipoproteinemias
Interventions
ObicetrapibDrug
10 mg Obicetrapib tablet
PlaceboDrug
placebo tablet made to resemble active
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC]Time frame: 84 Days
Locations
96 sites in 10 countries. Site status is shown where the registry gives one.
Site 01022
Jonesboro, Arkansas
Site 01015
Toluca Lake, California
Site 01009
Sarasota, Florida
Site 01023
Boise, Idaho
Site 01018
Chicago, Illinois
Site 01012
Iowa City, Iowa
Site 01007
Baton Rouge, Louisiana
Site 01005
Port Gibson, Mississippi
Site 01006
St Louis, Missouri
Site 01011
Lincoln, Nebraska
Site 01004
Norfolk, Nebraska
Site 01002
Morristown, New Jersey
Site 01010
New Providence, New Jersey
Site 01001
North Massapequa, New York
Site 01020
Morganton, North Carolina
Site 01019
Winston-Salem, North Carolina
Site 01008
Chattanooga, Tennessee
Site 01016
El Paso, Texas
Site 01013
Houston, Texas
Site 01014
Suffolk, Virginia
Site 06007
Brampton, Canada
Site 06008
Chicoutimi, Canada
Site 06005
Halifax, Canada
Site 06003
Montreal, Canada
Site 06009
Montreal, Canada
Site 06004
Québec, Canada
Site 06006
Sherbrooke, Canada
Site 06001
Vancouver, Canada
Site 06002
Victoria, Canada
Site 02006
Brno, Czechia
Site 02002
Hradec Králové, Czechia
Site 02003
Prague, Czechia
Site 02005
Prague, Czechia
Site 02004
Prague, Czechia
Site 02001
Uherské Hradiště, Czechia
Site 022001
Batumi, Georgia
Site 022003
Tbilisi, Georgia
Site 022004
Tbilisi, Georgia
Site 022010
Tbilisi, Georgia
Site 022006
Tbilisi, Georgia
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.